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Abstract
Purpose—Early phase clinical trials (EPTs) have led to new, more effective treatment options for 
children with cancer. Despite the extensive use of EPTs in pediatric oncology, little is known about 
parent and child experiences during EPT participation. The purposes of this pilot study were to 
assess the feasibility and preliminary results of having children with cancer and their parents 
complete measures of treatment burden and quality of life (QOL) concurrent with EPT 
participation.
Methods—In this descriptive, longitudinal, pilot study, parents and children were followed for 
the first 60 days of an EPT. Feasibility was assessed by participant enrollment and retention, and 
completion of measures. Measures completed included: Demographic form (completed at 
baseline); Diary of Trial Experiences to capture treatment burden (completed ongoing); and 
PedsQL™ Quality of Life Inventories, Cancer Modules, and Family Impact Module (completed at 
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baseline, post-first disease evaluation, and off-study). Data were analyzed using descriptive 
statistics.
Results—Feasibility goals of enrollment, retention, and measure completion were partially met. 
Preliminary treatment burden and QOL results are provided.
Conclusions—While QOL assessments may provide insight into EPT experiences, future 
studies need to be conducted at multiple sites and enrollment goals must account for participant 
attrition.
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Early phase clinical trials (EPTs) are the first steps to test novel medical therapies in humans 
(Kim et al., 2008; Lee, Skolnik, & Adamson, 2005). The process of developing therapies 
involves a series of clinical trials in humans; after preclinical testing, therapies are tested in 
phase I, phase II and/or pilot, and phase III clinical trials in order to obtain sufficient 
evidence of the therapy’s safety and efficacy (National Institutes of Health, n.d.). For the 
purposes of this study, EPTs include phase I, phase II, and pilot trials of investigational 
therapies that are still under development and not yet approved by the United States Food 
and Drug Administration. The challenge with pediatric EPTs is that, due to the 
investigational nature of the therapies being tested, children can only participate in an EPT 
when standard therapies are considered ineffective. The median life expectancy of children 
with relapsed cancer enrolled in a phase I clinical trial is between just 3.6 – 6.4 months 
(Bautista et al., 2015; Kim et al., 2008; Morgenstern et al., 2014).
Treatment burden is defined as the physical, financial, time, psychosocial, and procedural 
demands that a treatment places on a patient and their family, as well as its impact on patient 
and family functioning (Eton et al., 2012; Sav, Kendall, et al., 2013; Sav, King, et al., 2013). 
Treatment burden is a dynamic, multidimensional concept that fluctuates over time due to 
severity of the patient’s condition, development of toxicities, and adjustment to the 
treatment. Treatment burden is different from burden caused by other factors such as 
symptoms or disease, because it is based on treatment for the disease, and not on either the 
natural history or natural symptoms of the disease (Sav, King, et al., 2013). In adult patients, 
treatment burden encompasses time lost from work and other activities (Henry et al., 2008). 
Although children may not work, their time lost is equally important and burdensome; they 
would also benefit from spending the time required for treatments with family and friends or 
carrying out their usual activities. Although research has yet to confirm this, experts 
hypothesize that for children with chronic illness, treatment demands such as injections, 
blood samples, and dietary restrictions may be particularly burdensome and negatively 
impact children’s quality of life (QOL) (Henry et al., 2008; Ziaian et al., 2006).
A better understanding of treatment burden in the context of EPTs may help healthcare 
professionals, patients, and parents to make more informed treatment decisions (Sav, 
Kendall, et al., 2013). Although adults’ participation in phase I clinical trials provides hope 
and a sense of purpose, there are also significant associated physical, emotional, and 
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practical burdens (Cohen et al., 2007; Cox, 1999; Moore, 2001; Wootten, Abbott, Siddons, 
Rosenthal, & Costello, 2011). The research with adults is not generalizable to pediatric 
EPTs because children are reliant on parents as providers, caregivers, teachers, moral 
compasses, disciplinarians, and proxy decision-makers. Some experts suggest that EPTs 
burden children with additional medical procedures and toxicities, negatively impact QOL, 
limit palliation opportunities, and disrupt dying and bereavement processes (Beardsmore & 
Fitzmaurice, 2002; Oberman & Frader, 2003). Recent evidence, however, has demonstrated 
that an active palliative care program can ensure that measures of end-of-life care (e.g., 
presence or timing of do not attempt resuscitation orders, hospice use or length of stay) are 
not impacted by enrollment in a phase I clinical trial.(Levine et al., 2015) Although research 
on experiences of communication and decision-making during EPT consent processes has 
been conducted, knowledge is lacking regarding parent and child experiences of treatment 
burden and QOL while participating in an EPT. Therefore, the purposes of this pilot study 
were to assess the feasibility and preliminary results of having children with cancer and their 
parents complete measures of treatment burden and QOL concurrent with EPT participation.
Methods
This was a descriptive, longitudinal, pilot study with data collected from parents and 
children. Institutional Research Board approval was obtained for this study prior to enrolling 
participants. All parents and children aged ≥18 provided written documentation of informed 
consent; children 7 – 17 years of age provided verbal assent for participation. Recruitment 
occurred between June 2011 and May 2013.
All recruitment occurred at a large, Midwestern pediatric medical center. Parents and 
children were approached to participate after confirmation of their eligibility with the 
attending oncologist. The recruitment goal was 20 parent and child dyads. As this was a 
pilot study, the sample size was based on participants available (i.e. annual EPT enrollment 
projections at the pediatric medical center), rather than on statistical power (Leon, Davis, & 
Kraemer, 2011; Thabane et al., 2010). A 24-month maximum length was set on recruitment.
Child inclusion criteria were: (1) age 2 to 25 years; (2) receipt of at least one therapy prior to 
the EPT (i.e., phase I, phase II, or pilot clinical trial); (3) consented to participate in an 
outpatient-based EPT for relapsed/refractory pediatric cancer; (4) EPT therapy did not 
include 131I-metaiodobenzylguanidine (131I-MIBG) or oncolytic virotherapy; (5) enrolled 
within 48 hours of first dose of EPT therapy; and (6) ability to communicate in English. 
Parent inclusion criteria were: (1) age ≥18; (2) self-identification as biological parent or 
legal guardian of child; and (3) fluency in English. Eligibility criteria were established to 
prospectively capture the full experience of participation in a classic EPT where therapy 
involves either oral or intravenous agent(s) administered on a regular schedule to a child 
with relapsed and/or refractory cancer. To capture as full a data set as possible, an extended 
range of child ages was included based on ages covered by the PedsQL modules. EPTs 
involving 131I-MIBG therapy and oncolytic virotherapy were excluded due to the unique 
requirements of these studies that necessitated prolonged isolation from support systems. 
The first 48 hours was selected to ensure that baseline data reflected experiences at the time 
the EPT started.
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Procedures
Children were followed for either eight weeks (if length of treatment course was four weeks) 
or nine weeks (if length of treatment course was three weeks) during the EPT. This variance 
was due to a desire to standardize the time on study, while ensuring that children completed 
this study at the end of an EPT course. Assessments were completed at baseline, post-first 
disease evaluation, and end of this study. The baseline assessment was completed after the 
child was enrolled in the clinical trial, preferably before treatment started, but no more than 
48 hours after the administration of the first dose of the investigational therapy. The post-
disease evaluation assessment was completed after the first disease evaluation was 
performed, but no more than 7 days after the child/family were provided the results of the 
disease evaluation. The off-study assessment was completed at the end of a course, after the 
child had been on the EPT for 60 (+/− 5) days. In addition, parents were asked to complete 
the Diary of Trial Experiences on an ongoing basis (i.e. two to three times a week) at home. 
To ensure completeness, a study team member reviewed diary entries with the parent every 5 
to 14 days throughout the study. Table 1 provides a list of measures completed with each 
assessment, and by which participants. Participants received $25 in cash upon completion of 
the baseline and post-disease evaluation assessments, and $50 in cash after completing the 
off-study assessment.
Measures
Family Demographics—Parents completed an investigator-designed Family and Patient 
Demographic form at the baseline assessment. In addition to standard demographics, data 
included family composition, type of central line access, whether central line access was 
placed specifically for the EPT, and distance from primary household to pediatric medical 
center in miles and minutes of travel time.
Child Performance Status—The child’s Lansky or Karnofsky scale scores were 
evaluated at each assessment by a member of the health care team and documented in the 
clinical trial record. These scales are similar with the Lansky scale applicable for children 
less than 16 years of age and the Karnofsky for those aged 16 years and older. Both scales 
(1) quantify cancer patients’ general well-being and activities of daily life, (2) have well-
established reliability and validity, (3) are responsive to change, (4) are widely used, and (5) 
use a single score of 0 to 100 in increments of 10, where 0 is death and 100 is normal health 
with no complaints (Lansky, List, Lansky, Ritter-Sterr, & Miller, 1987; Schag, Heinrich, & 
Ganz, 1984; Vincent, Laliberte, Morris, & Wiemann, 1984).
EPT Data—Using an investigator-designed form, the study team extracted data from the 
EPT protocol, consent form, and the child’s EPT records. Data captured included: length of 
treatment course; frequency, number and duration of required and optional blood draws, 
physical exams, imaging, bone marrows, lumbar punctures, clinic visits and infusions; 
number of planned separate visits to a medical facility/laboratory; number of expected 
separate needle punctures; optional observations that the child/parent agreed to provide for 
the EPT (e.g. pharmacokinetic and pharmacogenetic samples); and outcomes of EPT disease 
evaluations.
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Treatment Burden—Based on an adaptation of the Collection of Indirect and Non-
medical direct costs (COIN) form (Sherman et al., 2001), the study team created the Diary 
of Trial Experiences to capture the treatment burden associated with EPT participation for 
parents and children. The COIN form was a feasible and practical method for assessing 
patient cost data in a study of 29 adult cancer patients being treated for prostate carcinoma 
(Sherman et al., 2001). Adaptations included reformatting and capturing time spent in 
different activities; financial costs associated with child care, lodging, and meals; 
venipunctures; and reasons why usual activities were missed. The additions were made by 
adding columns and rows as needed into the tables structuring the form, and by adding a 
separate section at the bottom of a page to capture venipunctures. The Diary of Trial 
Experiences was completed by parents on an ongoing basis and used to directly capture the 
number of appointments and activities related to the EPT, including time spent on and 
financial cost of those activities. See Table 2 for a listing of elements included in the diary.
QOL—The standardized and widely used PedsQL™ modules were used to assess QOL, 
including: the PedsQL™ Quality of Life Inventories (Standard Version), Cancer Modules, 
and Family Impact Module. The 21-to 23-item Quality of Life Inventories measure health-
related QOL in children and adolescents, with subscales for physical, emotional, social, and 
school functioning. The 25- to 27-item Cancer Modules measure elements of health-related 
QOL specific for children and adolescents with cancer, with subscales for pain and hurt, 
nausea, procedural anxiety, treatment anxiety, worry, cognitive problems, perceived physical 
appearance, and communication. The 36-item Family Impact Module measures parent 
physical, emotional, social, and cognitive functioning; communication; worry; family daily 
activities; and family relationships. For all modules, 5-point response options range from 
‘Never’ (100) to ‘Almost Always’ (0). The Likert scores were then transformed to a 0–100 
scale; as the items in PedsQL™ modules relate to problems, higher scores indicate better 
QOL and less problems. The total score for each module was determined by averaging the 
sum of all the scores for the items answered. A change of between 4.4 to 4.5 in the total 
score is the standard for a minimal clinically important difference in the PedsQL™ Quality 
of Life Inventories (Varni, Burwinkle, & Seid, 2005). Advantages to the PedsQL™ modules 
are their ease of completion, demonstrated internal consistency and reliability, and 
established responsiveness to change when repeatedly administered in short intervals 
(Banks, Barrowman, & Klaassen, 2008; Varni, Burwinkle, Katz, Meeske, & Dickinson, 
2002; Varni et al., 2005; Varni & Limbers, 2009; Varni, Seid, Knight, Uzark, & Szer, 2002; 
Varni, Seid, & Kurtin, 2001; Varni, Sherman, Burwinkle, Dickinson, & Dixon, 2004). For 
most children in this study (based on child’s age), both parent report and child self-report 
versions of the PedsQL™ Quality of Life Inventories and Cancer Modules were available, 
allowing parent and child to separately complete these modules. The parent completed the 
Family Impact Module.
Statistical Analyses
All data were analyzed using descriptive statistics. Since children were enrolled in EPTs 
with varying course lengths, treatment burden per week was calculated for each participant 
as the sum of entries in the Diary of Trial Experiences for course 1 of the EPT divided by the 
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number of weeks per course. Descriptive statistics of treatment burden per week were then 
calculated.
Feasibility was assessed by the following criteria: (1) ≥75% enrollment of all eligible parent 
and child dyads; (2) ≥ 80% retention of participants at the post-disease evaluation 
assessment; (3) ≥90% of questions answered by parents and children on each measure. 
Retention was evaluated as the rate of completion of the post-disease evaluation assessment 
by the 13 dyads who enrolled in the study, as completion of one course in the EPT was 
considered the minimum to be evaluable for this study. The same instruments were 
completed at the post-disease evaluation and off-study assessments, so selecting the post-
disease evaluation provided a full set of data to be compared with the baseline assessment 
and ensured that the experiences of children who were only in the EPT for one course were 
captured.
Results
Family Demographics, Child Performance Status, and EPT Data
The accrued sample consisted of 13 parent and child dyads. The children were mostly 
female (69.2%) and white (76.9% white, 15.4% black, 7.7% other). The mean age of the 
children was 11.4 years old (SD=4.9, range 4–20) and the mean number of children in the 
household was 1.8 (SD=1.2, range 0–4). More than half of the children had some sort of 
central venous access in place (Port=38.5%, PICC=15.4%). Parents’ annual income levels 
were fairly evenly distributed across categories (<$20,000=15.4%; $20–$40,000=23.1%; 
$40–$60,000=23.1%; $60–100,000=23.1%; >$100,000=15.4%), and the majority of parents 
had attended college or had a professional degree (93.3%). Mean distance of the primary 
household from the medical center was 78.8 miles (SD=96.0, range 2–300) or 80.8 minutes 
(SD=70.6, range 15–240). The median baseline performance score of the children was 90 
(SD=9.0, range 70–100). The children were participating on five different EPT protocols. 
See Table 3 for descriptive statistics summarizing requirements across the five EPT 
protocols.
Aim 1: Feasibility
Enrollment of Eligible Parent and Child Dyads—As shown in Figure 1, of the 
parents and children approached to participate (n = 15), only one parent and child dyad 
declined to participate (92.9% participation rate). However, one child was determined to be 
ineligible following consent due to communication difficulties resulting from a brain tumor, 
resulting in final enrollment of 13 of the 15 dyads approached to participate (86.7% 
enrollment rate). Both percentages were above the criteria of ≥75% enrollment, indicating 
that recruitment to this pilot study met feasibility criteria.
Retention of Eligible Parent and Child Dyads—Per Figure 1, three children (23.1%) 
deteriorated due to disease progression or suffered sufficient toxicities to be withdrawn from 
the EPT prior to their first disease evaluation. Thus, the criteria of 80% of study participants 
remaining on this study and completing the post-disease evaluation assessment was not quite 
met (76.9% retention was achieved at this time point). Overall, only seven children (53.8% 
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completion rate) remained on this study at the off-study assessment conducted 60 (+/− 5) 
days after enrollment, although no parent and child dyads were lost from this study for 
reasons other than the child’s removal from the associated EPT.
Completion of Measures—Each review of the Diary of Trial Experiences with the 
parent required between 5 – 15 minutes to complete. The reviews were either done while the 
parent was waiting at the medical center, or a study team member contacted the parent over 
the telephone. The Diary of Trial Experiences was too complicated to be completed by most 
participants without some assistance. Thus, rather than completing the diary at home on an 
ongoing basis, most parents waited and completed the form during a review with the study 
team member. Some questions on the diary were either too uncomfortable or too difficult for 
most participants to answer, and many participants elected to not provide that information. 
See Table 2 for a listing of elements of the diary that were observed by study team members 
to be easier and more difficult to answer. Overall, the feasibility criteria of 90% of the Diary 
of Trial Experiences being successfully completed before the review with a study team 
member was not met.
QOL measures were generally all completed, with only two individual child PedsQL™ 
modules missed during an assessment due to study team errors. The baseline assessment 
required between 20 – 40 minutes to complete, and was usually completed at the medical 
center either prior to or during an appointment (in a waiting room, clinic appointment room, 
or in their own room while inpatient). Two parents elected to complete their baseline 
PedsQL™ modules at home and return them at the next visit. The post-disease evaluation 
and off-study assessments required between 15 – 30 minutes to complete and all were done 
while the parent and child were waiting at the medical center.
There was minimal missing data from both parents and children on individual PedsQL™ 
modules. One parent did not respond to any of the five questions in the PedsQL™ Quality of 
Life Inventory related to school functioning (78.3% completion of that module) and two 
questions related to treatment anxiety on a PedsQL™ Cancer Module (92.6% completion). 
In addition, three other parents did not respond to one question in an individual PedsQL™ 
module (95.6 – 96.3% completion). Three different children did not answer one of the 
questions in one PedsQL™ module (95.6 – 96.3% completion). One child did not respond to 
five questions related to social functioning on a PedsQL™ Quality of Life Inventory (78.3% 
completion of that module). Overall, the children completed 99.4% of the questions on 52 
individual PedsQL™ modules they were provided to complete, while the parents completed 
99.5% of the questions on 87 modules. There were no detectable patterns to the questions 
not answered. However, many parents and children were observed by study team members 
as having difficulty answering questions related to school, particularly since many children 
were not attending school due to the advanced stage of their cancer and the PedsQL™ 
modules do not provide ‘Not Applicable’ as a response option. Thus, the school functioning 
subscale of the PedsQL™ Quality of Life Inventories likely resulted in inconsistent data. 
Overall, the feasibility criteria of 90% of the questions answered on each measure by parents 
and children was met.
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Aim 2: Preliminary Results for Treatment Burden and QOL
Treatment Burden—Table 4 provides the descriptive statistics of per week treatment 
burden for parent and child dyads who completed the post disease evaluation assessment 
(n=10). Median data suggest that at least half of the children had an average of 3.8 
appointments per week, requiring an average of 11.5 hours of time and 2.8 needle punctures 
per week, and resulting in an average of 9.9 hours of missed activities and $10.60 in out of 
pocket costs per week. Appointment hours included overnight admissions for observation 
experienced by 70% of the children for their first dose of EPT therapy. These overnight 
admissions were for monitoring and collection of timed pharmacokinetic laboratory 
specimens and were considered as one 24-hour long appointment. Children’s missed 
activities included school, attending camp, and family activities, and were almost entirely 
due to EPT appointments, with only three children missing activities due to not feeling well.
QOL—Figure 2A shows mean child and parent PedsQL™ Quality of Life Inventories scores 
at each assessment. While emotional health scores reported by both parents and children 
increased over time, other scores did not follow a continuous pattern. In general, children 
self-reported higher QOL scores than their parents reported on their behalf. The exception to 
this was the physical health summary score at post-disease evaluation and the psychosocial 
health summary score at baseline, which the parents generally reported as higher than their 
child. Statistical comparison could not be performed due to the small sample size.
Figure 2B shows mean child and parent Cancer Modules scores at each assessment. While 
the total scores reported by both parents and children increased over time, patterns of change 
for the other subscales varied over time. A wide variation between parent and child reports 
occurred for the communication subscale at both baseline and post-disease evaluation, with 
children self-reporting much lower scores than their parents on their behalf. Children 
generally reported higher procedural anxiety subscale scores than parents did at all time 
points, but particularly for the post-disease evaluation assessment; higher procedural anxiety 
subscale scores indicate less anxiety associated with needle sticks and other procedures 
performed as part of the child’s cancer care. Again, statistical analyses were not performed 
due to the small sample size.
Figure 2C shows the mean Family Impact Module scores as reported by parents at each 
assessment. Patterns of change on the worry and communication subscales varied over time, 
while the remaining scores continuously improved through the EPT. The overall total scores 
on this module were stable but low at all time points, indicating that the child’s cancer had a 
significant impact on the family. In particular, parents reported notably lower scores on the 
worry subscale, indicating that parents were very worried about their child’s cancer.
Discussion
The first major finding of this pilot study was that feasibility was not clearly established. 
While the goal of ≥ 75% enrollment was met, the goals for recruitment and retention were 
not met. In particular, the overall recruitment goal of 20 dyads was not achieved despite 
recruiting over a 24-month period. Challenges to recruitment included a slow accrual to 
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non-131I-MIBG and oncolytic virotherapy EPTs and lack of sufficient study team members 
to approach all potential participants.
The primary retention challenge was that attrition was higher than expected; although the 
goal of ≥ 80% retention was not quite met, no participants opted to leave this study early. All 
attrition was due to the child’s removal from the EPT due to either toxicity or disease 
progression. While this was an anticipated problem, given the limited life expectancy of 
children with cancer enrolled in EPTs, feasibility was impacted by this attrition (Bautista et 
al., 2015; Kim et al., 2008; Morgenstern et al., 2014). An important implication for future 
research with this population is to ensure that data is captured at multiple time points, 
starting before the end of the first course of therapy in the EPT, to ensure that attrition does 
not prohibit capturing the experiences of participants who are unable to remain in the EPT.
In terms of measure completion, the goal of ≥90% of questions being answered on each 
measure was met for the PedsQL™ measures, but not for the Diary of Trial Experiences. 
This diary proved to be overly complicated to complete without the assistance of a study 
team member. While treatment burden data were captured using the diary, it is clear that 
revisions to both the format and content are needed to enhance the diary’s usability and 
acceptability.
To improve feasibility, the following suggestions are recommended for future studies. First, 
to maximize recruitment efforts and minimize bias in those approached to participate, 
recruitment should clearly and systematically be tasked to multiple study team members. In 
addition, future research should be conducted at multiple sites or within a cooperative group 
to enhance recruitment and generalizability of findings. Lastly, the format of the Diary of 
Trial Experiences should be revised to mimic EPT medication diaries (i.e. one diary per 
course of therapy, with one line in the diary to be completed each day of the course).
The second major finding was that while some interesting insights were provided by 
completion of the PedsQL™ modules, it is less clear that the Diary of Trial Experiences has 
sufficient value to be worth pursuing in future research. While it may be useful to obtain 
quantitative results regarding EPT treatment burden, in its current form this diary only 
measures objective elements of treatment burden (i.e. number of medications, number of 
appointments, and time at appointments). The subjective elements of treatment burden, 
including the different perceptions patients and their family have of a treatment’s burden, are 
not captured. These perceptions include intangible elements that significantly impact the 
experience of treatment burden, such as difficulty administering oral medications to a young 
child, the meaning attributed to side-effects of the treatment, and beliefs about a treatment’s 
effectiveness (Sav, King, et al., 2013). Qualitative research would be needed to identify 
subjective elements for inclusion. For the Diary of Trial Experiences to be valuable, it 
should be able to identify children or families who would benefit from further support or 
allow families to specify their need for further support. However, in its current format this 
diary does not seem to perform any better than standard psychosocial assessments already 
being done by social workers and other health care providers.
CRANE et al. Page 9
J Pediatr Oncol Nurs. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The third major finding was that preliminary results suggest there is value in having parents 
and children complete QOL measures during EPT participation. Although the PedsQL™ 
measures have been widely used in a variety of settings, the authors found no evidence of 
their use in early phase pediatric oncology clinical trials, prior to this study. In particular, 
having both parents and children separately complete the PedsQL™ modules, provided 
insight that there may be time points when parents’ and children’s perceptions of indicators 
of the child’s quality of life may substantively differ. An example of this is the wide 
variation between parent and child reports on the PedsQL™ Cancer module communication 
subscale at baseline and post-disease evaluation, which suggests that children may have had 
more difficulty communicating concerns related to their cancer at these times than their 
parents were aware of. This discord between child and parent reports has been 
acknowledged as prevalent whenever a concern is not directly observable (e.g. when asking 
about pain, communication, and personal experiences) (Varni, Katz, Seid, Quiggins, & 
Friedman-Bender, 1998; Varni, Limbers, & Burwinkle, 2007). In this population, it is 
unlikely that the school functioning subscale of the PedsQL™ Quality of Life Inventories 
will produce valid results since many children participating in EPTs do not regularly attend 
school and ‘Not Applicable’ is not a response option. In a study of the QOL of children with 
advanced cancer, Tomlinson, Hinds, Bartels, Hendershot, and Sung (2011) also reported 
significant missing data for the school functioning subscale. A larger study of the use of 
QOL measures during EPT participation is necessary to better elucidate the value they 
provide. In future research, to more fully understand the impact of EPT participation on 
physical health, it would be helpful to capture occurrence of toxicities along with 
completion of QOL measures. The use of PROMIS Pediatric measures (i.e. Physical 
Functioning - Mobility, Physical Functioning - Upper Extremity, Pain Interference, Fatigue, 
Depression, Anxiety, and Peer Relationships) should also be considered in future research 
(Hinds et al., 2013).
An additional result was that all participants in this study reported minimal financial burden 
directly associated with EPT participation. In particular, the reported financial burden was 
not grossly observed to correlate with other data, such as distance traveled. In contrast, for 
adults with chronic illness financial burden has emerged as the most problematic element of 
treatment burden (Sav, Kendall, et al., 2013). Potential explanations for this finding include: 
(1) Parents were unwilling to report monetary burdens; (2) Parents were unable to accurately 
track monetary burdens; (3) Strong levels of financial support were offered by the pediatric 
medical center through foundations that support families of children with cancer; and, (4) 
Baseline socioeconomic demographic characteristics of parents and children enrolling in a 
pediatric oncology EPT may differ from the general population of adults with chronic 
illness.
The results of this pilot study are limited by small sample size, use of a single site for 
recruitment, the wide inclusion age range resulting in participants aged 4 to 20 years, and 
attrition of study participants. In particular, only a preliminary presentation of QOL results 
was possible. A problem affecting all studies of this population, including ours, is that the 
interpretation of results is hampered by the bias created by participant attrition. Children 
with the most toxicities and disease progression do not remain on study to complete follow-
up assessments.
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Conclusions
This avenue of research is important, and likely to be feasible if conducted at multiple sites 
or within a cooperative group. To date, no studies have considered the impact of EPT 
participation, in terms of burden and QOL impact, on children with cancer and their 
families. Instead, current research focuses on how QOL is impacted by the child’s current 
health status; the impact of treatment burden on QOL has not yet been considered. While it 
is unclear whether the Diary of Trial Experiences, as an objective measure of treatment 
burden, is worthy of further research, this pilot study highlights that measures of QOL 
impact of EPT participation can feasibly be completed by children with cancer who are 
participating in an EPT and their parents, and may provide valuable insights that could guide 
personalized interventions.
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Figure 1. 
Study Recruitment and Retention
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Figure 2. 
Mean PedsQL™ Scores at Each Assessment
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Table 1
Instruments Completed by Participants at Each Assessment
Instrument Baseline Assessment Post Disease Evaluation Assessment Off-Study Assessment
Child and Family Demographics Form Parent ---------- ----------
Diary of Trial Experiences Completed Throughout Study by Parent
PedsQL™ Quality of Life Inventories Parent and Child Parent and Child Parent and Child
PedsQL™ Cancer Modules Parent and Child Parent and Child Parent and Child
PedsQL™ Family Impact Module Parent Parent Parent
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Table 2
Elements from the Diary of Treatment Experiences
Easily Answeredq Difficult to Answer
• Type of services child used (e.g. oncology clinic, family doctor, 
emergency room, imaging, lab draw, parking, lodging, meals, 
and child care)
• Number of times services used
• Amount of time spent at medical service visits
• Out of pocket costs associated with medical services, parking 
and lodging
• Number of venipunctures, finger sticks, port access, and central 
line accesses
• Type of activities child missed
• Amount of time child missed at activities
• Reason activities were missed by child or parent
• Out of pocket costs associated with 
transportation, child care, and meals
• Type of activities parent missed
• Amount of time parent missed at activities
• Estimated loss of pay due to activities parent 
missed
• Insurance coverage for medical services and 
other services
• Other financial coverage for medical services 
and other services
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Table 3
Summary of Total EPT Course 1 Protocol Requirements*
Item Median Mean SD Range
Length of Course (weeks) 4 3.8 0.4 3 – 4
Baseline Imaging (number of scans) 2.5 2.8 1.2 2 – 5
Physical Exams (number) 4 3.8 0.4 3 – 4
Required Blood Draws (number) 12 11.3 4.7 4 – 16
Optional Blood Draws (number) 2.5 1.8 1.5 0 – 3
End of Course Imaging (number of scans) 2 1.5 1.2 0 – 3
Total Required Observations 20.5 19 5.9 10 – 26
*
n=5 different EPT protocols
J Pediatr Oncol Nurs. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CRANE et al. Page 20
Table 4
Descriptive Statistics for Treatment Burden Per Week Documented in the Diary of Trial Experiences During 
EPT Course 1*
Treatment Burden Per Week Median Mean SD Range
Number of Appointments 3.8 3.4 0.8 2.3 – 4.3
Time for Appointments (hours) 11.5 11.6 2.7 7.9 – 17.8
Activities Child Missed (hours) 9.9 15.6 13.2 2.3 – 37.5
Out of Pocket Cost ($) 10.6 15.6 16.5 0 – 50
Number of Needle Punctures 2.8 2.7 1 0.5 – 4.3
Note. Children were enrolled in EPTs with varying course lengths. Per week treatment burden was calculated for each participant as the total of 
entries in the Diary of Trial Experiences for course 1 of the EPT, divided by the number of weeks.
*
n = 10 parent and child dyads completing the post-disease evaluation assessment
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